Kura Oncology (NASDAQ:KURA) Given New $28.00 Price Target at Jefferies Financial Group

Kura Oncology (NASDAQ:KURA) had its target price decreased by research analysts at Jefferies Financial Group from $32.00 to $28.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 152.71% from the company’s current price.

Several other analysts have also recently commented on KURA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday. HC Wainwright increased their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. JMP Securities reissued a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday. Finally, Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.43.

Kura Oncology Trading Down 30.4 %

Shares of KURA stock opened at $11.08 on Thursday. The stock has a fifty day simple moving average of $18.28 and a two-hundred day simple moving average of $19.82. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17. The firm has a market capitalization of $861.58 million, a PE ratio of -4.95 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. lifted its position in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares during the last quarter. Vanguard Group Inc. lifted its position in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares in the last quarter. Armistice Capital LLC grew its holdings in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Kura Oncology during the first quarter worth $110,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.